{
  "docId": "019de070-5583-7544-b7b3-e17a9a5a1395",
  "docSlug": "6e951aba00c366c61ecceffedb425cf6",
  "documentTitle": "Alkermes | Results Presentation Deck | 12 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 12,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 11,
  "notes": "The chart displays 11 data points representing quarterly prescription volume from Q1'18 to Q3'20.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5583-7544-b7b3-e17a9a5a1395/9",
  "deckHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395",
  "deckJsonHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395.json",
  "deckAnchorHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.625,
        "w": 0.645,
        "x": 0.043,
        "y": 0.256
      },
      "kind": "chart",
      "text": "ARISTADA Quarterly TRx MOT",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03aa2c4c-18af-4983-99da-9ff4053cefd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.305,
        "x": 0.675,
        "y": 0.256
      },
      "kind": "list",
      "text": "Q3 year-over-year growth of 22% on TRx months of therapy (MOT) basis; Outpaced overall atypical long-acting injectable (LAI) market Q3 year-over-year growth of 5%; Market share: TRx MOT: 9% of atypical LAI market prescriptions in August 2020; Utilization of two-month dose drove 37% of ARISTADA Q3'20 volume in terms of MOT",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28a81f04-611b-4b09-bf04-30fcbfd978ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.07,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Source: IMS NPA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c631457-9f62-49c9-9415-ff39c7172ba9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.365,
        "x": 0.037,
        "y": 0.095
      },
      "kind": "title",
      "text": "ARISTADA®: Prescription Growth Trends",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "572d0280-e57c-4686-8ce7-6c3e27ac0999",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 7,
      "beatId": "be501d72-f2a1-4ef2-8ee5-253442163c72",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The product performance slides show satisfaction with VIVITROL and ARISTADA",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}